Marjanu Hikmah Elias1, Husin Azlan2, Sarina Sulong3, Abdul Aziz Baba4, Ravindran Ankathil3. 1. Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Nilai, Malaysia. 2. Haemato-Oncology Unit, Department of Internal Medicine, Universiti Sains Malaysia Hospital, Kota Bharu, Malaysia. 3. Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia. 4. International Medical University, Kuala Lumpur, Malaysia.
Abstract
BACKGROUND: Imatinib mesylate is a molecularly targeted tyrosine kinase inhibitor drug. It is effectively used in the treatment of chronic myeloid leukemia (CML) patients. However, development of resistance to imatinib mesylate as a result of BCR-ABL dependent and BCR-ABL independent mechanisms has emerged as a daunting problem in the management of CML patients. Between these mechanisms, BCR-ABL independent mechanisms are still not robustly understood. AIM: To investigate the correlation of HOXA4 and HOXA5 promoter DNA hypermethylation with imatinib resistance among CML patients. METHODS AND RESULTS: Samples from 175 Philadelphia positive CML patients (83 good response and 92 BCR-ABL non-mutated imatinib resistant patients) were subjected to Methylation Specific High Resolution Melt Analysis for methylation levels quantification of the HOXA4 and HOXA5 promoter regions. Receiver operating characteristic curve analysis was done to elucidate the optimal methylation cut-off point followed by multiple logistic regression analysis. Log-Rank analysis was done to measure the overall survival difference between CML groups. The optimal methylation cut-off point was found to be at 62.5% for both HOXA4 and HOXA5. Chronic myeloid leukemia patients with ≥63% HOXA4 and HOXA5 methylation level were shown to have 3.78 and 3.95 times the odds, respectively, to acquire resistance to imatinib. However, overall survival of CML patients that have ≤62% and ≥ 63% methylation levels of HOXA4 and HOXA5 genes were found to be not significant (P-value = 0.126 for HOXA4; P-value = 0.217 for HOXA5). CONCLUSION: Hypermethylation of the HOXA4 and HOXA5 promoter is correlated with imatinib resistance and with further investigation, it could be a potential epigenetic biomarker in supplement to the BCR-ABL gene mutation in predicting imatinib treatment response among CML patients but could not be considered as a prognostic marker.
BACKGROUND:Imatinib mesylate is a molecularly targeted tyrosine kinase inhibitor drug. It is effectively used in the treatment of chronic myeloid leukemia (CML) patients. However, development of resistance to imatinib mesylate as a result of BCR-ABL dependent and BCR-ABL independent mechanisms has emerged as a daunting problem in the management of CMLpatients. Between these mechanisms, BCR-ABL independent mechanisms are still not robustly understood. AIM: To investigate the correlation of HOXA4 and HOXA5 promoter DNA hypermethylation with imatinib resistance among CMLpatients. METHODS AND RESULTS: Samples from 175 Philadelphia positive CMLpatients (83 good response and 92 BCR-ABL non-mutated imatinib resistant patients) were subjected to Methylation Specific High Resolution Melt Analysis for methylation levels quantification of the HOXA4 and HOXA5 promoter regions. Receiver operating characteristic curve analysis was done to elucidate the optimal methylation cut-off point followed by multiple logistic regression analysis. Log-Rank analysis was done to measure the overall survival difference between CML groups. The optimal methylation cut-off point was found to be at 62.5% for both HOXA4 and HOXA5. Chronic myeloid leukemiapatients with ≥63% HOXA4 and HOXA5 methylation level were shown to have 3.78 and 3.95 times the odds, respectively, to acquire resistance to imatinib. However, overall survival of CMLpatients that have ≤62% and ≥ 63% methylation levels of HOXA4 and HOXA5 genes were found to be not significant (P-value = 0.126 for HOXA4; P-value = 0.217 for HOXA5). CONCLUSION: Hypermethylation of the HOXA4 and HOXA5 promoter is correlated with imatinib resistance and with further investigation, it could be a potential epigenetic biomarker in supplement to the BCR-ABL gene mutation in predicting imatinib treatment response among CMLpatients but could not be considered as a prognostic marker.
Authors: Daniel W Sherbenou; Oliver Hantschel; Ines Kaupe; Stephanie Willis; Thomas Bumm; Lalita P Turaga; Thoralf Lange; Kim-Hien Dao; Richard D Press; Brian J Druker; Giulio Superti-Furga; Michael W Deininger Journal: Blood Date: 2010-06-02 Impact factor: 22.113
Authors: Wenyong W Zhang; Jorge E Cortes; Hui Yao; Li Zhang; Neelima G Reddy; Elias Jabbour; Hagop M Kantarjian; Dan Jones Journal: J Clin Oncol Date: 2009-06-08 Impact factor: 44.544
Authors: Raed A Alharbi; Hardev S Pandha; Guy R Simpson; Ruth Pettengell; Krzysztof Poterlowicz; Alexander Thompson; Kevin Harrington; Mohamed El-Tanani; Richard Morgan Journal: Oncotarget Date: 2017-08-07
Authors: Marjanu Hikmah Elias; Abdul Aziz Baba; Azlan Husin; Sarina Sulong; Rosline Hassan; Goh Ai Sim; S Fadilah Abdul Wahid; Ravindran Ankathil Journal: Biomed Res Int Date: 2012-12-26 Impact factor: 3.411